HealthEconomics.Com

Connected. Community.

  • facebook
  • linkedin
  • twitter
  • vimeo
  • rss
  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute
You are here: Home / Comparative Effectiveness Research / ICER: Osteoporosis Anabolic Agents Priced Too High

ICER: Osteoporosis Anabolic Agents Priced Too High

In a Final Evidence Report on the comparative clinical effectiveness and value of teriparatide and abaloparatide, the Institute of Clinical and Economic Review (ICER) found the price of both agents was “too high.”

ICER logo for Berger reportTeriparatide and abaloparatide are anabolic agents used in osteoporosis treatments.

“Evidence suggests that, for the right patients, both teriparatide and abaloparatide provide benefit over no treatment, but the limited availability of data from head-to-head trials makes it difficult to ascertain whether the agents are more effective than existing alternatives, such as biophosphonates,” ICER Chief Medical Officer Dr. David Rind said in a press release.

Rind added the pricing of the agents is “too high in proportion to the benefit the provide, contributing to potential access barriers for patients.”

According to the release, an independent panel during the California Technology Assessment Forum also voted on evidence presented in the report.

The panel, among other things, found there was not enough evidence to suggest treatment with teriparatide and abaloparatide offers greater benefits over zoledronic acid.

Click here to read the Final Evidence Report on ICER’s website.

The full press release can be read here.



You might also be interested in:

  • New Program in Pharmaceutical Value Assessment and… 01/22/2021
  • HealthEconomics.Com, Scientist.Com Announce HEOR, RWE Partnership 04/10/2020
  • Matthew McHugh Appointed Director for Health Outcomes and… 02/10/2021
  • Government, Big Pharma, and The People: A Century of Dis-Ease 12/03/2020
  • Using AI, NLP and Data Visualization with RWE to Generate… 06/10/2020
  • Key Innovations Coming From The Next Generation of PBM’s 08/12/2020
  • Tufts Analyzes Cost-Effectiveness Analysis for 1974-2018 07/28/2020

 

View All JobsPost a JobView Current NewsletterSubscribe to Newsletters
Conference of the Week:

Link of the Week:

Job of the Week:

Webinar of the Week:

White Papers

  • Whitepaper: The Role of Centralized Care Management in Value-based Care
  • 2017 In-Depth Outlook on Oncology Report
  • Value-Based Healthcare: Making it Happen
  • Value-Based Contracting for Biopharmaceuticals Moves Forward
  • ICER Releases White Paper on Gene Therapy

Syndicated Reports

  • HTA in Europe: Key Success Factors for Positive HTA Recommendations
  • Paying for Digital Health: Payer Insights
  • Benchmarking Pharma’s MSL Capabilities
  • Biosimilars: US Payer Perspectives
  • KAM Metrics: Driving Efficiency, Measuring Success
HealthEconomics.Com

HealthEconomics.Com

  • News
  • Conferences
  • Reports
  • Jobs
  • Consulting
  • Newsletters
  • White Papers

More Links

  • Jobs
  • Education
  • Graduate Schools
  • Webinar Services

Support & Contact

  • Contact Us

About

  • About Us
  • Advertise
  • Webinar Services
  • HE Institute
  • Testimonials
  • Privacy Policy

Stay Connected

  • facebook
  • twitter
  • linkedin
  • pinterest
  • google-plus
  • youtube
  • rss

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.

HEALTHECONOMICS HZ SMALL V2

HE Institute

Strategy, Training, Education, and Communications in HEOR & Market Access.

Innovation Webinar

Big ideas accelerating change in HEOR, RWE and Health Technology. Learn more!

tHEORetically Speaking Blog

Insights and observations for HEOR, market access, pricing, reimbursement, and health policy.

HE Jobs Portal

Your Premier Employment Source for HEOR, Market Access, and Real World Evidence

HE Webinars

Online educational and informational seminars for HEOR, market access, pricing, and reimbursement.
  • HealthEconomics.Com
  • About HealthEconomics.Com
  • Advertising Inquiries
  • Careers
  • Contact HealthEconomics.Com

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities, proving news, education, jobs, resources, policy updates, consulting, advertising, all available via website, newsletters, and social media.

© 2017 Health Economics. All rights reserved.

  • News
  • Jobs
    • HE Jobs Portal
    • View all Jobs
    • Post a Job
  • Value, Evidence and Access Marketplace
    • Visite the Marketplace
    • On-demand Webinar
  • Industry Events
    • HealthEconomics.Com Webinars
    • View Conferences
    • View Webinars
  • Newsletters
    • Subscribe
    • View All
  • Blog
  • Resources
    • Value Communication
    • Free Marketing Consultation!
    • The Future of Print Medical Journals: How to Stay Relevant
    • Be a Better Writer
    • White Papers
    • Education Resources
    • Syndicated Reports
    • Books
    • Databases
    • Blogs
      • HE-Artists
      • Podcasts
  • HE Institute